What Do We Know About the Belviq Lawsuits?

Belviq (lorcaserin hydrochloride) was originally developed by San Diego-based Arena Pharmaceuticals, Inc. The drug is really a serotonin 2C receptor agonist for weight loss marketed as a medication for adults who're obese and suffer from a weight-related condition, like type 2 diabetes, high blood pressure, or high cholesterol.

On February 13, 2020, the U.S. Food & Drug Administration (FDA) announced so it had requested the voluntary recall of Belviq and Belviq XR from the market. The FDA's Drug Safety Communication warned of an elevated occurrence of cancer in a long-running clinical trial of the drugs. Predicated on these studies, the FDA concluded that the risks of Belviq outweigh its benefits.

This announcement came approximately one month after the FDA had issued an alert about the possible carcinogenic nature of the medication, also referred to as lorcaserin.

Belviq Injuries & Side Effects

In 2012, the FDA approved Belviq with the necessity that drug manufacturer Eisai conduct clinical trials about the danger of cardiovascular problems associated using its weight-loss medication. Within the course of five years, 12,000 obese patients with various cardiovascular disease risk factors participated in a randomized, double-blind, placebo-controlled clinical trial.

The analysis that followed the trials was published in 2018. It indicated no meaningful difference in cardiovascular safety between groups who used Belviq and people who used the trial's placebo. However, the analysis revealed a potential connection between Belviq and cancer. The analysis mentioned cancer cases in the two trial groups, reporting 215 cases in the Belviq group and 210 cases in the placebo group.

The Belviq lawsuits claim that the utilization of Belviq can increase the chance of cancer, especially colorectal, pancreatic, and lung cancer.

Our law firm is no more accepting Belviq injury cases.

What Do We Know Concerning the Belviq Lawsuits?

Belviq (lorcaserin hydrochloride) was originally developed by San Diego-based Arena Pharmaceuticals, Inc. The drug is a serotonin 2C receptor agonist for weight management marketed as a medication for adults that are obese and suffer with a weight-related condition, like type 2 diabetes, high blood pressure, or high cholesterol.

For more details kindly visit Belviq lawsuit.